Atrogin1/MAFbx is an ubiquitin ligase that mediates muscle atrophy in a variety of catabolic states. We recently found that H 2 O 2 stimulates atrogin1/MAFbx gene expression. Since the cytokine tumor necrosis factor-␣ (TNF-␣) stimulates both reactive oxygen production and general activity of the ubiquitin conjugating pathway, we hypothesized that TNF-␣ would also increase atrogin1/MAFbx gene expression. 
Muscle wasting is a debilitating complication of cancer, AIDS, and other chronic inflammatory diseases. Loss of muscle mass results primarily from accelerated protein degradation via the ubiquitin-proteasome pathway (1) . Proteins degraded by this mechanism are first covalently linked to a chain of ubiquitin molecules, which marks them for rapid breakdown by the 26S proteasome (2) . The selectivity of ubiquitin targeting to protein substrates is primarily a function of ubiquitin ligases (E3 proteins), a family of enzymes that catalyze the transfer of activated ubiquitin from a specific ubiquitin carrier (E2) protein to a lysine residue on the substrate.
In skeletal muscle, three E3 proteins are known to regulate ubiquitin conjugation in catabolic states: E3␣, atrogin1/MAFbx, and MuRF1. E3␣ interacts with E2 14k to attach ubiquitin to protein substrates according to the "N-end rule" (3) . Atrogin1/MAFbx and MuRF1 are up-regulated and appear to be essential for accelerated muscle protein loss in a variety of experimental models of catabolism. These include fasting, diabetes, cancer, renal failure, hindlimb suspension, immobilization, denervation, sepsis, and lipopolysaccharide administration (4 -8) . Because the atrogin1/MAFbx and MuRF1 genes respond to such diverse catabolic conditions, it is important to determine the cellular mechanisms that regulate expression of these genes.
In studies of atrogin1/MAFbx regulation, we recently found that mRNA levels are increased by exposing muscle cells to exogenous H 2 O 2 (9) . Skeletal muscle myocytes continuously generate H 2 O 2 and other reactive oxygen species (ROS) that function as intracellular signaling molecules (10) . ROS production (11, 12) and ROS-mediated signaling (13, 14) are stimulated by tumor necrosis factor-␣ (TNF-␣), a catabolic cytokine (15) that increases general activity of the ubiquitin conjugating pathway (16 -18) . Therefore, as observed for H 2 O 2 , we hypothesized that TNF-␣ would up-regulate atrogin1/MAFbx expression in skeletal muscle. The present study tested this hypothesis, measuring changes in mRNA levels and ubiquitin conjugating activity in muscle cells stimulated by TNF-␣. Our approach incorporated several experimental preparations including differentiated myotubes, excised muscles, and TNF-␣-treated mice. Responses to TNF-␣ were compared with those elicited by H 2 O 2 , a positive control.
We evaluated mitogen-activated protein kinases (MAPKs) as potential second messengers for TNF-␣. Data from nonmuscle cell types indicate that TNF-␣ and H 2 O 2 activate MAPKs, including p38, ERK1/2, and JNK (13) . p38 MAPK has been identified as a potential regulator of muscle catabolism (19) . Recent studies show that p38 activity in skeletal muscle is elevated by procatabolic states, which include limb immobilization (20) , acute quadriplegic myopathy (21), Type 2 diabetes (22) , neurogenic atrophy (21) , and aging (23) . To test p38 MAPK involvement in atrogin1/MAFbx regulation, we measured TNF-␣ effects on total and phosphorylated enzyme levels in muscle and tested the effects of p38 MAPK inhibitors on TNF-␣-stimulated atrogin1/MAFbx gene expression. Control studies screened ERK1/2 and JNK for similar involvement.
Our results suggest the atrogin1/MAFbx gene product is up-regulated in response to TNF-␣, an event that precedes the rise in general ubiquitin conjugating activity. Atrogin1/MAFbx up-regulation in response to either TNF-␣ or H 2 O 2 is associated with activation of p38 MAPK, ERK1/2, and JNK. The former appears to be essential for atrogin1/MAFbx up-regulation since p38 inhibitors block increases in gene expression and ubiquitin conjugating activity.
MATERIALS AND METHODS
Myocyte responses to TNF-␣ were tested using several complementary preparations. Primary studies of postreceptor signaling events and atrogin1/MAFbx gene expression were conducted using differentiated C2C12 mytubes. Physiological relevance was assessed using excised mouse diaphragm preparations challenged with recombinant TNF-␣ in vitro or limb muscles of mice that were preinjected with TNF-␣. Details of these preparations are outlined below.
Myogenic cell cultures
Myotubes were cultured from the murine skeletal musclederived C2C12 myoblast line (American Type Culture Collection, Rockville, MD, USA) as described previously (24) . Briefly, C2C12 cells were cultured in DMEM supplemented with 10% fetal calf serum and gentamicin at 37°C in the presence of 5% CO 2 . Myoblast differentiation was initiated by replacing the growth medium with differentiation medium: DMEM supplemented with 2% horse serum. Differentiation was allowed to continue for 96 h before experimentation (changing to fresh medium at 48 h). Recombinant murine TNF-␣ (Roche Applied Science, Indianapolis, IN, USA) was added to differentiation medium for incubation with myotubes as indicated. H 2 O 2 (Sigma Chemicals, St. Louis, MO, USA) was incubated with myotubes in DMEM supplemented with 0.5% horse serum.
Animal use
Experimental protocols were approved in advance by the Animal Protocol Review Committee of the Baylor Animal Program. Adult C57 mice (8-wk-old) were injected intraperitoneally (IP) with 100 ng/g body weight of recombinant murine TNF-␣ (PeproTech, Rocky Hill, NJ, USA) or with an equal volume of diluent. At indicated times, animals were deeply anesthetized by IP injection of pentobarbital sodium 85 mg/kg and gastrocnemius muscles were surgically removed for Northern blot analysis. In separate studies, the diaphragm muscle was excised from anesthetized mice that had not been conditioned. Muscles then were directly exposed to TNF-␣ by incubation in vitro.
Northern blot analysis
Total RNA was isolated from rat or C2C12 myotubes by using the RNAzol reagent (TEL TEST, Friendswood, TX, USA). Twelve g of each sample was isolated by agarose gel electrophoresis as modified from the procedure described by Liu and Chou (25) . Briefly, RNA samples were denatured by heating to 65°C for 3 min in a sample loading buffer containing 1ϫ TBE, 6.5% ficoll, 0.005% bromphenol blue, 0.025% xylkene cyanol ff, and 3.5 M urea (final concentrations). Samples were immediately chilled on ice and separated with 1% native agarose gel at 8 V/cm. RNA was blotted and UV cross-linked to GeneScreen membrane (NEN Life Science Products, Boston, MA, USA). Prehybridization (4 h) and hybridization (16 h) were carried out in ULTRAhyb buffer (Austin, TX, USA) at 42°C. The hybridization probe for the atrogin1/MAFbx gene was the full-length human coding sequence prepared from isolated total RNA using a one-step RT-PCR kit (Qiagen, Valencia, CA, USA) and labeled with [␣-
32 P]dCTP (3000 Ci/mmol, Amersham Pharmacia, Arlington Heights, IL, USA) using the random primer method. After hybridization, the membranes were washed and exposed to X-ray films. Levels of mRNA were quantified by analyzing autoradiographs using densitometry software (ImageQuant 5.2, Molecular Dynamics, Sunnyvale, CA, USA); the optical density of each band was normalized using the corresponding 18S signal.
Western blot analysis
Protein content of each sample was determined by BCA protein assay (Pierce, Rockford, IL, USA). Lysates of C2C12 myotubes (80 g protein/lane) or protein extracts made from the heart (40 g), diaphragm (40 g), and gastrocnemius (80 g) were separated by 12% SDS-PAGE and transferred to nitrocellulose membranes. After incubation with a blocking buffer, the membranes were incubated with antiphospho-ERK1/2, anti-phospho-p38, anti-phospho-JNK, anti-ERK1/2, anti-p38, or anti-JNK (Cell Signaling Technology, Beverly, MA, USA). Horseradish peroxidase-conjugated secondary antibodies were used to locate the primary antibodies by the enhanced chemiluminescence method. Bands detected on the X-ray films were quantified using densitometry software (ImageQuant). Differences between experimental conditions were limited to comparisons within a given muscle type: myotubes, diaphragm, or gastrocnemius.
Ubiquitin conjugation assay
Whole cell extracts of C2C12 myotubes were made by three freeze-thaw cycles followed by 30 min incubation at 4°C in a buffer containing 20 mM Tris-HCl, pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 1 g/mL leupeptin, and 2 g/mL aprotinin. Extracts were dialyzed against a buffer containing Tris-HCl, pH 7.6, 1 mM DTT, and 10% glycerol. Protein was determined by the Bio-Rad protein assay reagent.
125 I-Ubiquitin was prepared by iodination of ubiquitin (Sigma) with carrier free sodium 125 I (Amersham Pharmacia). Dialyzed extracts (ϳ100 g protein) were incubated with 125 I-Ub (ϳ100,000 cpm) in a buffer containing 20 mM Tri-HCl, pH 7.6, 20 mM KCl, 5 mM MgCl 2 , 1 mM DTT, 10% glycerol, 30 M MG-132 (to inhibit proteasome activity), 1 M ubiquitin aldehyde (to inhibit the hydrolysis of ubiquitin conjugates by deubiquitinating isopeptidases), and 2 mM AMPPNP. AMPPNP is an ATP analog that provides energy for activation of ubiquitin by E1 but not for degradation of ubiquitinated proteins by the proteasome (26) . The reaction mixtures (20 L total volume) were incubated at 37°C for 60 min, after which the reaction was terminated by addition of 20 L of 2ϫ Laemmli sample buffer (27) . The mixture was heated to 90°C for 3 min and separated on SDS-PAGE (15% gel). To quantify ubiquitin conjugating activity, autoradiographs of the gel were analyzed using densitometry software (ImageQuant).
Statistics
Commercial software (SigmaStat, SPSS Science, Chicago, IL, USA) was used to analyze data. Student's t test was used for individual comparisons. Multiple comparisons were assessed by 1-way ANOVA or regression analysis. Differences between groups were considered significant at the P Ͻ 0.05 level.
Values are reported as means Ϯ se.
RESULTS

TNF-␣ up-regulates atrogin1/MAFbx gene expression in muscle
TNF-␣ effects on atrogin1/MAFbx expression were tested by Northern blot analyses. Using a full-length cDNA probe, we observed that differentiated C2C12 myotubes constitutively express atrogin1/MAFbx mRNA ( Fig. 1) . We detected multiple transcripts as reported by Gomes et al. (5); these ranged from ϳ6.5 to ϳ2.4 kb. Myotubes were analyzed after incubation with recombinant murine TNF-␣ 6 ng/mL, a concentration shown to induce myotube protein loss (24) . Atrogin1/MAFbx mRNA levels increased 96.3 Ϯ 21.1% (PϽ0.01, nϭ11) after 2 h, then returned to control level at 6 h ( Fig. 1) , remaining unchanged at 12 and 24 h (data not shown).
As shown in Fig. 2 , constitutive expression of atrogin1/ MAFbx mRNA was also detected in gastrocnemius muscles of adult mice. The sizes of transcripts detected in mouse muscle are similar to those seen in C2C12 myotubes, although the relative abundance of individual transcripts differs. Intraperitoneal injection of TNF-␣ 100 ng/g increased atrogin1/MAFbx mRNA content by 76.2 Ϯ 17.1% after 4 h (PϽ0.05, nϭ3) and 87.7 Ϯ 10.1% after 6 h (PϽ0.05, nϭ3), a prolonged response relative to the transient up-regulation seen in myotubes (Fig. 1 ). This sustained elevation may reflect time-dependent absorption and delivery of the cytokine, in vivo amplification of the original TNF-␣ stimulus, or both. 
TNF-␣ stimulates MAPK phosphorylation
To elucidate signaling events by which TNF-␣ might regulate atrogin1/MAFbx gene expression, we systematically examined TNF-␣ effects on MAPK activity in differentiated C2C12 myotubes. Western blot analysis using phosphospecific antibodies was used to assess enzyme activation. As shown in Fig. 3A , phosphorylation of p38 MAPK was increased within 30 min of exposing myotubes to TNF-␣ 6 ng/mL but total p38 content was unaltered. H 2 O 2 300 M, another stimulus known to up-regulate atrogin1/MAFbx (9) Fig. 3B) and JNK (Fig. 3C ) without altering total enzyme levels. The p38 MAPK responses measured in cultured myotubes were replicated using skeletal muscle preparations isolated from adult mice. As shown in Fig. 4 , in vitro exposure of isolated hemidiaphragms to TNF-␣ 500 ng/mL stimulated an increase in p38 phosphorylation relative to data obtained from contralateral hemidiaphragms incubated in buffer alone. Direct exposure of isolated hemidiaphragms to H 2 O 2 300 M had similar effects, stimulating p38 phosphorylation without altering total enzyme content. Control experiments confirmed that ERK1/2 phosphorylation was increased by exposing isolated hemidiaphragms to either TNF-␣ or H 2 O 2 (data not shown).
TNF-␣ effects on p38 MAPK and atrogin1/MAFbx are dose dependent
To evaluate the relationship between p38 phosphorylation and atrogin1/MAFbx expression, we measured changes in each parameter after exposing myotubes to TNF-␣ concentrations ranging from 6 to 60,000 pg/ mL. The p38 MAPK data are shown in Fig. 5 . Densitometry indicates a dose-dependent increase in the phospho-to-total p38 ratio, evidence of progressive p38 activation by TNF-␣. Figure 6 shows a similar response by atrogin1 mRNA. Myotube content of both transcripts appeared to increase with TNF-␣ concentration. Normalized for 18 s mRNA levels, averaged values for total atrogin1 mRNA showed a clear dose-dependent increase. Figure 7 shows that atrogin1/MAFbx upregulation was positively related to p38 MAPK activation. Small increases in enzyme phosphorylation were associated with marked elevation of atrogin1/MAFbx mRNA levels, suggesting p38 MAPK might influence atrogin1/MAFbx expression.
p38 MAPK inhibition blocks atrogin1/MAFbx upregulation by TNF-␣
Causality was assessed by use of pharmacological probes. Data in Fig. 8 show that SB203580, a selective p38 inhibitor (28), blunted up-regulation of the atrogin1/MAFbx gene in TNF-␣-treated myotubes. The ERK inhibitor PD98059 (29) had less effect; SP600125, a JNK inhibitor (30) , and DMSO had none. p38 MAPK involvement was reinforced by follow-up studies in which H 2 O 2 up-regulation of atrogin1/MAFbx was inhibited by SB203580 but not PD98059 (data not shown). Functional importance of these effects was tested by measuring general activity of the ubiquitin conjugating pathway. We previously showed that TNF-␣ stimulates activity of this pathway (18) . This response is illustrated in Fig. 9 , where ubiquitin conjugating activity is increased in C2C12 myotubes 6 h after TNF-␣ exposure. Cell lysates were analyzed with Western blot using an antibody against the phosphorylated form of p38, ERK1/2, or JNK, and an antibody against total p38, ERK1/2, or JNK. Arrows indicate samples that were exposed to TNF-␣ or H 2 O 2 . Optical density data from 4 independent experiments were analyzed by Student's t test.
Pretreatment with the p38 inhibitor SB203580 inhibited this response. On average, the ERK inhibitor PD98059 did not. Subsequent studies showed that curcumin 25 M, a second inhibitor of p38 activation (31) , also prevented increases in atrogin1/MAFbx gene expression and ubiquitin conjugating activity stimulated by either TNF-␣ or H 2 O 2 (data not shown).
DISCUSSION
The current study demonstrates that differentiated skeletal muscle cells up-regulate the atrogin1/MAFbx Figure 4 . TNF-␣ and H 2 O 2 activate p38 MAPK in mouse diaphragm. Mouse diaphragm was excised and incubated in Krebs-Ringer's solution bubbled with 95%-5% O 2 -CO 2 at room temperature. One hemidiaphragm from each animal was exposed to TNF-␣ 500 ng/mL or H 2 O 2 300 M for 30 min (arrows). The contralateral hemidiaphragm was exposed to the buffer only. Protein extracts prepared from the hemidiaphragms were analyzed by Western blot for p38 activation by use of a phosphospecific antibody. Optical density data from 4 hemidiaphragm pairs were analyzed by Student's t test. Figure 5 . TNF-␣ effects on p38 MAPK phosphorylation are dose dependent. C2C12 myotubes were exposed to TNF-␣ at the indicated concentrations for 2 h and protein was extracted for Western blot analysis. Upper panel shows original blots from 3 experiments. Extracts were analyzed for phosphorylated p38 (left) and total p38 (right). Lower panel depicts the averaged ratios of phospho-to-total p38 (Ϯse) at each TNF-␣ concentration as calculated from densitometry data. TNF-␣ increased this ratio in a dose-dependent manner; P Ͻ 0.001 by ANOVA. gene when stimulated by TNF-␣. This response is associated with increased activity of the ubiquitin conjugating pathway and appears to be mediated by p38 MAPK signaling. These findings advance our understanding of the transcriptional mechanisms that regulate muscle catabolism and suggest potential targets for therapeutic intervention.
TNF-␣ and the atrogin1/MAFbx gene
Circulating TNF-␣ levels are elevated in a wide variety of conditions including cancer, AIDS, congestive heart failure, and COPD: chronic inflammatory diseases where muscle wasting presents a lethal threat to patients (15) . Evidence that circulating TNF-␣ promotes muscle catabolism was first obtained in studies of animals treated with exogenous TNF-␣ (32, 33), transgenic animals that overexpressed TNF-␣ (34), and animals with experimental diseases that elevate endogenous TNF-␣, i.e., sepsis (35) or tumor implantation (36) . Subsequently it was demonstrated that TNF-␣ acts directly on cultured myotubes to stimulate loss of muscle protein (24) .
The downstream target of catabolic signaling in TNF-␣-stimulated muscle appears to be the ubiquitinproteasome pathway. Intravenous administration of TNF-␣ to rodents increases ubiquitin content and ubiquitin-conjugated protein levels in muscle (16) and in vitro incubation with TNF-␣ increases ubiquitin mRNA in rat limb muscle (17) . We recently demonstrated that TNF-␣ stimulates activity of the ubiquitin conjugating pathway in differentiated myotubes by up-regulating expression of UbcH2, an E2 protein highly expressed in striated muscle (18) .
The present study demonstrates that TNF-␣ also stimulates expression of the gene for a key E3 protein, atrogin1/MAFbx. This gene is constitutively expressed in both differentiated myotubes and adult mouse skeletal muscle, suggesting atrogin1/MAFbx plays a physiological role in regulating protein turnover. Atrogin1/ MAFbx involvement in muscle atrophy was established by Gomes et al. (5) and Bodine et al. (4) , who demonstrated that the gene is up-regulated in experimental models of catabolism that included fasting, diabetes, cancer, renal failure, hindlimb suspension, immobilization, and denervation. Atrogin1/MAFbx is also upregulated in animal models of experimental sepsis (7, 8) and in differentiated myotubes exposed to H 2 O 2 (9) or glucocorticoids (37) . The functional importance of atrogin1/MAFbx is evident in atrogin1/MAFbx-deficient mice, which are resistant to experimentally in- duced muscle atrophy (4), suggesting up-regulation of this gene is critical for muscle catabolism. The current study is the first to demonstrate atrogin1/MAFbx upregulation in response to cytokine stimulation. The data identify an additional transcriptional mechanism by which TNF-␣ may induce muscle wasting and reinforce the potential importance of TNF-␣ as a catabolic stimulus in inflammatory disease.
Regulation of the atrogin1/MAFbx gene by p38 MAPK
TNF-␣ clearly activates all three major MAPK signaling pathways in skeletal muscle. However, inhibitor studies suggest that atrogin1/MAFbx expression preferentially responds to p38 MAPK. p38 is a stress-activated protein kinase that responds to a variety of stimuli, including oxidative stress and TNF-␣ (38) , and has been identified as a likely mediator of catabolic signaling in skeletal muscle (19) . This is consistent with a recent report by Di Giovanni et al. (21) that constitutive p38 phosphorylation is elevated in atrophic muscles of patients with acute quadriplegic myopathy. Microarray data from these muscles showed a concurrent elevation of gene products related to the ubiqutin-proteasome pathway, including atrogin1/MAFbx. The same study also demonstrated increased p38 phosphorylation in muscles of individuals with neurogenic muscle atrophy. Childs and associates (20) found that experimental immobilization of the rat hindlimb for 10 days caused a 128% increase in p38 phosphorylation. This was associated with a 38% decrease in soleus muscle mass over the same period. Other procatabolic conditions in which constitutive phosphorylation of skeletal muscle p38 has been shown to be elevated include Type 2 diabetes (22) and aging (23) .
Our current data suggest the atrogin1/MAFbx gene is a downstream target of p38 MAPK signaling. This is consistent with the concept that pathologic elevation of p38 activity favors protein degradation and muscle atrophy. The present study does not identify the immediate target of p38 kinase activity or the mechanism by which p38 increases atrogin1/MAFbx mRNA levels. An attractive possibility is that p38 MAPK contributes to the activation of Foxo (forkhead-type) transcription factors (39). Sandri and associates (40) and Stitt et al. (41) recently identified Foxo as an essential regulator of atrogin1/MAFbx expression in skeletal muscle. Both groups showed that Foxo is tonically inhibited by phosphoinositol-3-kinase (PI3K) and Akt and that decrements in PI3K/Akt signaling allow Foxo activity to increase, stimulating atrogin1/MAFbx expression and muscle atrophy (40, 41) . The possibility that p38 MAPK modulates the PI3K/Akt/Foxo pathway, either directly or indirectly, is a clear hypothesis for future testing.
ROS regulation of ubiquitin conjugating activity
Increased ROS activity and oxidative stress are closely associated with loss of muscle mass in catabolic states that include cancer (42) , chronic obstructive pulmonary disease (43) , congestive heart failure (44), aginginduced sarcopenia (45) , and immobilization (46) . TNF-␣ binding to surface receptors increases ROS activity within skeletal muscle fibers (12) and activates redox-sensitive transcription factors and protein kinases, including NF-B, AP-1, p38 MAPK, ERK1/2, and JNK (13) . Among these, NF-B has been shown to mediate TNF-␣-induced up-regulation of the UbcH2 gene (18) but not the atrogin1/MAFbx gene (9) . In the current study, we found that p38 activity and atrogin1/ MAFbx expression are both stimulated by H 2 O 2 and that the latter response is inhibited by p38 blockade. These data support a second messenger role for H 2 O 2 in TNF-␣ signaling and are consistent with observations Figure 9 . p38 MAPK mediates TNF-␣ stimulation of ubiquitin conjugating activity. C2C12 myotubes were preincubated with SB203580, PD98059, or DMSO for 30 min before 6 h incubation with TNF-␣. Cell extracts were prepared and analyzed for ubiquitin conjugating activity. Muscle proteins that incorporated 125 I-Ubiquitin were separated by SDS-PAGE and visualized by autoradiography. Ubiquitin conjugating activity was quantified by densitometry. Data from 5 experiments were analyzed by ANOVA with Tukey's multiple comparison test. *Different from control (PϽ0.05).
that H 2 O 2 stimulates expression of E2 and E3 proteins in differentiated myotubes and increases general activity of the ubiquitin conjugating pathway in the absence of TNF-␣ (9). 
